Downloading...
Download

Cobratrader13

$GLSI Releases Trial Data Soon- Keep It On Your WatchlistFundamental Analysis: Greenwich LifeSciences Inc. is a clinical-stage biopharmaceutical company that focuses on the development of a breast cancer immunotherapy treatment to prevent the recurrence of cancer following surgery. This treatment, GP2 , has been undergoing phase two clinical trials for a while, and the data from these trials will be released April 10-15, 2021. Considering the success in previous trials, the probability of the data being good is high. Technical Analysis: $GLSI is showing strong momentum coming off of a sizable dip, which shows strength and could mean that this trend will continue. In addition to that, we are experiencing very low volume at the moment, which means that as buyers come in in anticipation of these trials, it will have a larger impact on the price. My Outlook: Personally, I am planning on only playing the hype this week. I am anticipating strong hype growth this week. The risk on this name is extremely high, considering that if the phase 2 data disappoints phase 1 buyers, they are all likely to sell, which could potentially bring the price all the way back down to $5. The chance of the data being bad is relatively low, but the consequences if it happens to be are detrimental. I am planning on selling on Friday or as soon as they hit around $45. Like and Follow :) Good Luck! If you like these biotech ideas, follow @CobraTrader13 for weekly biotech watchlists.
NASDAQ:GLSILong
by Investor4321
$GLYC Releases Trial Data For Cancer Treatment On The 10thFundamental Analysis: GlycoMimetics, Inc. is a clinical-stage biotechnology company that focuses on developing glycomimetics that inhibit disease-related functions of carbohydrates. They are currently developing a treatment for hormone receptor-positive metastatic breast cancer . The drug, GMI-1359, has undergone phase one safety trials, and the data from these trials will be presented at AACR on April 10, 2021. Technical Analysis $GLYC is in a heavy buy zone and is forming the bullish double bottom pattern. In addition to that, the MACD has just crossed. My Outlook I am anticipating a steady rise this week as buyers trickle in anticipation of this data release. The share price could easily be $3.70 by Friday as we bounce from this. Since this is a phase one data release, it would be possible to play the post-release here as well. Because the drug is a cancer treatment, if the data is good, people will get extremely excited. With a market cap of $163M, there is no telling how high the price could soar after the release. Good Luck! If you like bio ideas like this, follow @CobraTrader13. He posts a biotech watchlist every week, with plenty of FDA hype plays like this one.
GLong
by Investor4321